Modification of sample size in group sequential clinical trials.
In group sequential clinical trials, sample size reestimation can be a complicated issue when it allows for change of sample size to be influenced by an observed sample path. Our simulation studies show that increasing sample size based on an interim estimate of the treatment difference can substantially inflate the probability of type I error in most practical situations. A new group sequential test procedure is developed by modifying the weights used in the traditional repeated significance two-sample mean test. The new test has the type I error probability preserved at the target level and can provide a substantial gain in power with the increase of sample size. Generalization of the new procedure is discussed.
Cui
L
L
Division of Biometrics I, OB/CDER, Food and Drug Administration, Rockville, Maryland 20852, USA. cuil@cder.fda.gov
Hung
H M
HM
Wang
S J
SJ
D001699:Biometry; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D006801:Humans; D011336:Probability; D018401:Sample Size